Abatacept
The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Anakinra.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Anakinra.
Advertisement
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Anakinra.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Anakinra.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Anakinra.
Advertisement
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Anakinra.
Canakinumab
The risk or severity of infection can be increased when Anakinra is combined with Canakinumab.
Certolizumab Pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Anakinra.
Advertisement
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Anakinra.
Fingolimod
Anakinra may increase the immunosuppressive activities of Fingolimod.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Anakinra.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Anakinra.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Anakinra.
Infliximab
The risk or severity of adverse effects can be increased when Anakinra is combined with Infliximab.
Infliximab-Abda
The risk or severity of adverse effects can be increased when Anakinra is combined with Infliximab.
Infliximab-Dyyb
The risk or severity of adverse effects can be increased when Anakinra is combined with Infliximab.
Leflunomide
The risk or severity of adverse effects can be increased when Anakinra is combined with Leflunomide.
Natalizumab
The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Anakinra.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Anakinra.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Anakinra.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Anakinra.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.
Rituximab
The risk or severity of adverse effects can be increased when Anakinra is combined with Rituximab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Anakinra.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Anakinra.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Anakinra.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Anakinra.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Anakinra.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Anakinra.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Tocilizumab
The risk or severity of adverse effects can be increased when Anakinra is combined with Tocilizumab.
Tofacitinib
The risk or severity of adverse effects can be increased when Anakinra is combined with Tofacitinib.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Anakinra.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Anakinra.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Anakinra.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Anakinra.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Anakinra.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Anakinra.
